UNSPSC 51434937: Hydralazine/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434937 Hydralazine/reserpine is a Commodity code representing pharmaceutical products state and local governments procure for emergency medical services, particularly advanced life support medications used by fire rescue departments and emergency responders. State and local purchasing offices, including city and county emergency services departments, issue competitive sealed bids and RFQs to supply these drugs to paramedic units and ambulance services. The scope of work involves supplying FDA-approved medications in injectable or tablet form, with strict requirements for expiration dating, storage stability, material defect warranties, and compliance with OSHA Hazard Communication Standards. Vendors must typically meet inventory and delivery windows as tight as ten days from order receipt and maintain replacement protocols for expired stock before the contractual nine-month minimum shelf life threshold.

The City of Tampa's Purchasing Department posted a representative opportunity in April 2026 (Bid No. 26P00188), an IFB for Advanced Life Support Medications for Tampa Fire Rescue in Hillsborough County, Florida, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with bids due April 8, 2026 and an estimated contract value of $40,000. The solicitation applied a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount (not to exceed $10,000) and required comprehensive accessibility documentation including WCAG 2.2 Level AA conformance reporting and Section 508 compliance. The contract term was one year from award with options to renew for two additional one-year periods plus unilateral extension rights for up to three 30-day periods. Recent activity on this code is limited to the single documented opportunity; geographic concentration and issuing-body breadth cannot be characterized from the available record.